1.
Wester R, van der Holt B, Asselbergs E, Zweegman S, Kersten MJ, Vellenga E, Kooy M van M, de Weerdt O, Minnema M, Lonergan S, Palumbo A, Lokhorst H, Broijl A, Sonneveld P. Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial. Haematologica 2019; 104(11):2265-2273; https://doi.org/10.3324/haematol.2018.205476.